Glucosylceramide (GlcCer)

Glucosylceramide is a glycosphingolipid consisting of a ceramide backbone (sphingosine linked to a fatty acid) with a glucose molecule attached via a glycosidic bond[1]. It is synthesized by the enzyme glucosylceramide synthase (GCS) and functions as a critical mediator of cell signaling, membrane structure, and lipid raft formation in cellular membranes[1]. Glucosylceramide accumulates pathologically in lysosomal storage disorders, particularly Gaucher disease, where deficient glucocerebrosidase activity leads to progressive lipid buildup[2][5]. Beyond rare genetic disorders, elevated glucosylceramide levels are implicated in type 2 diabetes, cancer drug resistance, Parkinson's disease, and cardiovascular disease[2][4][6][12]. While glucosylceramide itself is not directly drugged, inhibition of glucosylceramide synthase (GCS) has emerged as a validated therapeutic strategy called substrate reduction therapy[4]. Multiple GCS inhibitors are now approved or in clinical development, including eliglustat tartrate for Gaucher disease and compounds like venglustat for Fabry disease[4]. The primary therapeutic challenge lies in developing selective GCS inhibitors that avoid off-target effects on related glucosylceramidase enzymes and gastrointestinal glycosidases, while achieving adequate tissue penetration for neurological indications[2][4][10].

Other names

Glucosylcerebrosidecerebrosidesglycosphingolipid

Glucosylceramide synthase (GCS) inhibition reduces glucosylceramide biosynthesis through substrate reduction therapy Inhibition shifts the balance toward apoptotic ceramide, increasing apoptosis and decreasing drug resistance in cancer cells Lowers glucosylceramide concentrations to manageable levels for impaired glucocerebrosidase enzyme in Gaucher patients GCS inhibition improves insulin sensitivity in type 2 diabetes models